Mario Morgenstern1,2, Richard Kuehl3, Charalampos G Zalavras4, Martin McNally5, Werner Zimmerli6, Marc Antoine Burch2, Thomas Vandendriessche7, William T Obremskey8, Michael H J Verhofstad9, Willem Jan Metsemakers10. 1. Center for Musculoskeletal Infections, University Hospital Basel, Basel, Switzerland. 2. Department of Orthopaedic and Trauma Surgery, University Hospital Basel, Basel, Switzerland. 3. Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland. 4. Keck School of Medicine, University of Southern California, LAC+USC Medical Center, Los Angeles, California, USA. 5. The Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals, Oxford, UK. 6. Interdisciplinary Unit for Orthopaedic Infections, Kantonsspital Baselland, Liestal, Switzerland. 7. KU Leuven Libraries - 2Bergen - Learning Centre Désiré Collen, Leuven, Belgium. 8. Department of Orthopaedic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, United States. 9. Trauma Research Unit, Department of Surgery, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands. 10. Department of Trauma Surgery, University Hospitals Leuven, Leuven, Belgium.
Abstract
AIMS: The principle strategies of fracture-related infection (FRI) treatment are debridement, antimicrobial therapy, and implant retention (DAIR) or debridement, antimicrobial therapy, and implant removal/exchange. Increasing the period between fracture fixation and FRI revision surgery is believed to be associated with higher failure rates after DAIR. However, a clear time-related cut-off has never been scientifically defined. This systematic review analyzed the influence of the interval between fracture fixation and FRI revision surgery on success rates after DAIR. METHODS: A systematic literature search was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, in PubMed (including MEDLINE), Embase, and Web of Science Core Collection, investigating the outcome after DAIR procedures of long bone FRIs in clinical studies published until January 2020. RESULTS: Six studies, comprising 276 patients, met the inclusion criteria. Data from this review showed that with a short duration of infection (up to three weeks) and under strict preconditions, retention of the implant is associated with high success rates of 86% to 100%. In delayed infections with a fracture fixation-FRI revision surgery interval of three to ten weeks, absence of recurrent infection was reported in 82% to 89%. Data on late FRIs, with a fracture fixation-FRI revision surgery interval of more than ten weeks, are scarce and a success rate of 67% was reported. CONCLUSION: Acute/early FRI, with a short duration of infection, can successfully be treated with DAIR up to ten weeks after osteosynthesis. The limited available data suggest that chronic/late onset FRI treated with DAIR may be associated with a higher rate of recurrence. Successful outcome is dependent on managing all aspects of the infection. Thus, time from fracture fixation is not the only factor that should be considered in treatment planning of FRI. Due to the heterogeneity of the available data, these conclusions have to be interpreted with caution. Cite this article: Bone Joint J 2021;103-B(2):213-221.
AIMS: The principle strategies of fracture-related infection (FRI) treatment are debridement, antimicrobial therapy, and implant retention (DAIR) or debridement, antimicrobial therapy, and implant removal/exchange. Increasing the period between fracture fixation and FRI revision surgery is believed to be associated with higher failure rates after DAIR. However, a clear time-related cut-off has never been scientifically defined. This systematic review analyzed the influence of the interval between fracture fixation and FRI revision surgery on success rates after DAIR. METHODS: A systematic literature search was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, in PubMed (including MEDLINE), Embase, and Web of Science Core Collection, investigating the outcome after DAIR procedures of long bone FRIs in clinical studies published until January 2020. RESULTS: Six studies, comprising 276 patients, met the inclusion criteria. Data from this review showed that with a short duration of infection (up to three weeks) and under strict preconditions, retention of the implant is associated with high success rates of 86% to 100%. In delayed infections with a fracture fixation-FRI revision surgery interval of three to ten weeks, absence of recurrent infection was reported in 82% to 89%. Data on late FRIs, with a fracture fixation-FRI revision surgery interval of more than ten weeks, are scarce and a success rate of 67% was reported. CONCLUSION: Acute/early FRI, with a short duration of infection, can successfully be treated with DAIR up to ten weeks after osteosynthesis. The limited available data suggest that chronic/late onset FRI treated with DAIR may be associated with a higher rate of recurrence. Successful outcome is dependent on managing all aspects of the infection. Thus, time from fracture fixation is not the only factor that should be considered in treatment planning of FRI. Due to the heterogeneity of the available data, these conclusions have to be interpreted with caution. Cite this article: Bone Joint J 2021;103-B(2):213-221.
Authors: Markus Rupp; Nike Walter; Susanne Baertl; Siegmund Lang; David W Lowenberg; Volker Alt Journal: Bone Joint Res Date: 2021-11 Impact factor: 5.853
Authors: Ruth A Corrigan; Jonathan Sliepen; Maria Dudareva; Frank F A IJpma; Geertje Govaert; Bridget L Atkins; Rob Rentenaar; Marjan Wouthuyzen-Bakker; Martin McNally Journal: Antibiotics (Basel) Date: 2022-07-14
Authors: Martin McNally; Ruth Corrigan; Jonathan Sliepen; Maria Dudareva; Rob Rentenaar; Frank IJpma; Bridget L Atkins; Marjan Wouthuyzen-Bakker; Geertje Govaert Journal: Antibiotics (Basel) Date: 2022-07-14
Authors: Melissa Depypere; Jonathan Sliepen; Jolien Onsea; Yves Debaveye; Geertje A M Govaert; Frank F A IJpma; Werner Zimmerli; Willem-Jan Metsemakers Journal: Front Cell Infect Microbiol Date: 2022-07-07 Impact factor: 6.073
Authors: Jie Li; Ronald Man Yeung Wong; Yik Lok Chung; Sharon Shui Yee Leung; Simon Kwoon-Ho Chow; Margaret Ip; Wing-Hoi Cheung Journal: Bone Joint Res Date: 2022-02 Impact factor: 5.853